Nov 16, 2022 / 06:50PM GMT
Brad Canino - Stifel Financial Corp. - Analyst
Great. Thanks, everyone, again for joining the Stifel Healthcare Conference. My name is Brad Canino, senior biotech analyst here. Really happy to have Merus share the stage with us today for a fireside chat. And we've got the CEO, Bill Lundberg here to do that with us. Maybe just take a minute, introduce the company, and then we'll dive right into Q&A as always.
Bill Lundberg - Merus NV - CEO, President & Principal Financial Officer
Sure thing. So Merus is a company that develops antibody-based therapies for oncology. These are bispecific and trispecific or multispecific antibodies based on the common light chain format. There are a variety of different multispecific antibody formats. What's really cool about our technology is that we make essentially monoclonal antibodies, but they bind to two different things. They come out of a single cell. And with that, we can stand on decades of optimizing therapies based on monoclonal antibodies.
We can do true large-scale screening. We can do all of the Fc
Merus NV at Stifel Healthcare Conference Transcript
Nov 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers